Ali Emre Öz

Ali Emre Öz

Auto-generated profile, based on publicly available information

Ali Emre Öz

Department of Psychiatry, Faculty of Medicine Alanya Alaaddin Keykubat University Antalya Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 June 2026 in Academic Journal of Neuropsychiatry and Neuropsychology
Verified
Journal Article
Closed access
AUAbdullah Burak Uygur
Abdullah Burak Uygur
KKKadir Karakuş
Kadir Karakuş
SESelime Çelik Erden
Selime Çelik Erden
RÖRabia Önem
Rabia Önem
AÖAli Emre Öz
Ali Emre Öz
ŞSŞerifhan Mirac Sarı
Şerifhan Mirac Sarı
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional monoamine (serotonin/norepinephrine) hypothesis. This article reviews the mechanism of action, clinical adverse effects, contraindications, safe administration protocols, and treatment process associated with esketamine, one of these novel therapeutic approaches.